The availability of acetylcholinesterase inhibitors for the treatment of Alzheimer's disease raises a number of clinical and ethical questions. Many of the guidelines published in an attempt to tackle these questions lack either clinical or scientiยฎc validity. Against this background a model is prop
Treatment for Alzheimer's disease
โ Scribed by Gordon K Wilcock
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 46 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0885-6230
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Xanomeline is a novel muscarinic receptor agonist relatively devoid of parasympathomimetic side effects. Xanomeline had high affinity for muscarinic receptors and much lower affinity for a variety of other neuronal receptors in radioligand binding assays. Functional studies in cell lines transfected
There are two main approaches to the treatment of Alzheimer's disease. The ยฎrst approach is to prevent the neurodegenerative changes that ultimately cause irreversible damage to the brain. As the excessive formation of betaamyloid protein appears to play a primary role in the neurodegenerative proce